Pharmacogenomics and cancer stem cells: A changing landscape?

Trends in Pharmacological Sciences

Volumn 32, Issue 8, 2011, Pages 487-494

  Crea, Francesco ^a   Duhagon, Maria Ana ^b   Farrar, William L ^c   Danesi, Romano ^a  

^a UNIVERSITY OF PISA   (Italy)

^b DEPARTAMENTO DE BIOQUÍMICA   (Uruguay)

^c NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BREAST CANCER RESISTANCE PROTEIN; CD133 ANTIGEN; DICKKOPF 1 PROTEIN; DOXORUBICIN; GAMMA SECRETASE; IMATINIB; INTERLEUKIN 6; IRINOTECAN; NOTCH RECEPTOR; SONIC HEDGEHOG PROTEIN; WNT PROTEIN;

CANCER STEM CELL; CANCER THERAPY; CELL ACTIVITY; CELL FATE; CELL FUNCTION; CELL PROLIFERATION; CELL RENEWAL; CELL SURVIVAL; CLINICAL EFFECTIVENESS; CORRELATION ANALYSIS; DIAGNOSTIC IMAGING; DRUG ACTIVITY; DRUG SENSITIVITY; DRUG TRANSPORT; ENZYME ACTIVITY; GENE EXPRESSION PROFILING; GENETIC VARIABILITY; GENOTYPE; HUMAN; IMAGE ANALYSIS; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOME ASSESSMENT; PHARMACOGENOMICS; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; SIGNAL TRANSDUCTION; SURVIVAL TIME; TREATMENT RESPONSE; TUMOR XENOGRAFT;

ANIMALS; ANTINEOPLASTIC AGENTS; BIOLOGICAL MARKERS; CELL DIFFERENTIATION; CLINICAL TRIALS AS TOPIC; DRUG RESISTANCE, NEOPLASM; HUMANS; MICE; MODELS, BIOLOGICAL; NEOPLASMS; NEOPLASTIC STEM CELLS; PHARMACOGENETICS; SIGNAL TRANSDUCTION; TREATMENT OUTCOME;

EID: 79960966714     PISSN: 01656147     EISSN: 18733735     Source Type: Journal    
DOI: 10.1016/j.tips.2011.03.010     Document Type: Review

References (79)

1. D. Hanahan, and R.A. Weinberg The hallmarks of cancer Cell 100 2000 57 70 (Pubitemid 30046295)
2. J.H. Goldie Drug resistance in cancer: a perspective Cancer Metastasis Rev. 20 2001 63 68 (Pubitemid 34074680)
3. M.L. Maitland TPMT, UGT1A1 and DPYD: genotyping to ensure safer cancer therapy? Trends Pharmacol. Sci. 27 2006 432 437 (Pubitemid 44051569)
4. M. Schwab Role of genetic and nongenetic factors for fluorouracil treatment-related severe toxicity: a prospective clinical trial by the German 5-FU Toxicity Study Group J. Clin. Oncol. 26 2008 2131 2138
5. J.E. Dick Looking ahead in cancer stem cell research Nat. Biotechnol. 27 2009 44 46
6. L. Prestegarden Glioma cell populations grouped by different cell type markers drive brain tumor growth Cancer Res. 70 2010 4274 4279
7. M. Dean Tumour stem cells and drug resistance Nat. Rev. Cancer 5 2005 275 284 (Pubitemid 40488633)
8. T.S. Kuhn Historical structure of scientific discovery Science 136 1962 760 764
9. D. Bonnet, and J.E. Dick Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell Nat. Med. 3 1997 730 737 (Pubitemid 27298715)
10. C. Wu, and B.A. Alman Side population cells in human cancers Cancer Lett. 268 2008 1 9
11. M.M. Ho Side population in human lung cancer cell lines and tumors is enriched with stem-like cancer cells Cancer Res. 67 2007 4827 4833 (Pubitemid 46910191)
12. L. Patrawala Side population is enriched in tumorigenic, stem-like cancer cells, whereas ABCG2+ and ABCG2- cancer cells are similarly tumorigenic Cancer Res. 65 2005 6207 6219 (Pubitemid 40994406)
13. Broadley, K.W. et al. Side Population is not Necessary or Sufficient for a Cancer Stem Cell Phenotype in Glioblastoma Multiforme. Stem Cells, doi:10.1002/stem.582.
14. A.N. Shah Development and characterization of gemcitabine-resistant pancreatic tumor cells Ann. Surg. Oncol. 14 2007 3629 3637 (Pubitemid 350160137)
15. S. Desrivieres The biological functions of the versatile transcription factors STAT3 and STAT5 and new strategies for their targeted inhibition J. Mammary Gland Biol. Neoplasia 11 2006 75 87 (Pubitemid 44309191)
16. S.J. Dylla Colorectal cancer stem cells are enriched in xenogeneic tumors following chemotherapy PLoS ONE 3 2008 e2428
17. F. Yu Let-7 regulates self renewal and tumorigenicity of breast cancer cells Cell 131 2007 1109 1123 (Pubitemid 350235025)
18. F. Crea Targeting prostate cancer stem cells Anticancer Agents Med. Chem. 9 2009 1105 1113
19. G. Dontu Role of Notch signaling in cell-fate determination of human mammary stem/progenitor cells Breast Cancer Res. 6 2004 R605 615
20. F. Radtke, and K. Raj The role of Notch in tumorigenesis: oncogene or tumour suppressor? Nat. Rev. Cancer 3 2003 756 767 (Pubitemid 37328814)
21. V. Bolos Notch signalling in cancer stem cells Clin. Transl. Oncol. 11 2009 11 19
22. G. McKenzie Cellular Notch responsiveness is defined by phosphoinositide 3-kinase-dependent signals BMC Cell Biol. 7 2006 10
23. R.D. Meng gamma-Secretase inhibitors abrogate oxaliplatin-induced activation of the Notch-1 signaling pathway in colon cancer cells resulting in enhanced chemosensitivity Cancer Res. 69 2009 573 582
24. C. Giovannini Selective ablation of Notch3 in HCC enhances doxorubicin's death promoting effect by a p53 dependent mechanism J. Hepatol. 50 2009 969 979
25. R. Nusse Wnt signaling and stem cell control Cell Res. 18 2008 523 527 (Pubitemid 351630946)
26. P.J. Morin Activation of beta-catenin-Tcf signaling in colon cancer by mutations in beta-catenin or APC Science 275 1997 1787 1790 (Pubitemid 27136715)
27. K. Uematsu Activation of the Wnt pathway in non small cell lung cancer: evidence of dishevelled overexpression Oncogene 22 2003 7218 7221 (Pubitemid 37378553)
28. J. Shou Human Dkk-1, a gene encoding a Wnt antagonist, responds to DNA damage and its overexpression sensitizes brain tumor cells to apoptosis following alkylation damage of DNA Oncogene 21 2002 878 889 (Pubitemid 34146301)
29. T. Ohigashi Inhibition of Wnt signaling downregulates Akt activity and induces chemosensitivity in PTEN-mutated prostate cancer cells Prostate 62 2005 61 68 (Pubitemid 39614295)
30. J. Jiang, and C.C. Hui Hedgehog signaling in development and cancer Dev. Cell 15 2008 801 812
31. S. Liu Hedgehog signaling and Bmi-1 regulate self-renewal of normal and malignant human mammary stem cells Cancer Res. 66 2006 6063 6071
32. F. Varnat Human colon cancer epithelial cells harbour active HEDGEHOG-GLI signalling that is essential for tumour growth, recurrence, metastasis and stem cell survival and expansion EMBO Mol. Med. 1 2009 338 351
33. V. Clement HEDGEHOG-GLI1 signaling regulates human glioma growth, cancer stem cell self-renewal, and tumorigenicity Curr. Biol. 17 2007 165 172 (Pubitemid 46107823)
34. M. Ehtesham Ligand-dependent activation of the hedgehog pathway in glioma progenitor cells Oncogene 26 2007 5752 5761 (Pubitemid 47312811)
35. N.M. Alajez Targeted depletion of BMI1 sensitizes tumor cells to P53-mediated apoptosis in response to radiation therapy Cell Death Differ. 16 2009 1469 1479
36. F. Crea BMI1 silencing enhances docetaxel activity and impairs antioxidant response in prostate cancer Int. J. Cancer 128 2010 1946 1954
37. J.A. Kennedy Comment on "Tumor growth need not be driven by rare cancer stem cells" Science 318 2007 1722 author reply 1722
38. D. Beier Temozolomide preferentially depletes cancer stem cells in glioblastoma Cancer Res. 68 2008 5706 5715
39. R. Artells Tumour CD133 mRNA expression and clinical outcome in surgically resected colorectal cancer patients Eur. J. Cancer 46 2010 642 649
40. R. Pallini Cancer stem cell analysis and clinical outcome in patients with glioblastoma multiforme Clin. Cancer Res. 14 2008 8205 8212
41. H. Okayama CD44v6, MMP-7 and nuclear Cdx2 are significant biomarkers for prediction of lymph node metastasis in primary gastric cancer Oncol. Rep. 22 2009 745 755
42. A. Celebiler Cavusoglu Predicting invasive phenotype with CDH1, CDH13, CD44, and TIMP3 gene expression in primary breast cancer Cancer Sci. 100 2009 2341 2345
43. C.N. Oldenhuis Prognostic versus predictive value of biomarkers in oncology Eur. J. Cancer 44 2008 946 953
44. C.W. Ong CD133 expression predicts for non-response to chemotherapy in colorectal cancer Mod. Pathol. 23 2010 450 457
45. A. Murat Stem cell-related "self-renewal" signature and high epidermal growth factor receptor expression associated with resistance to concomitant chemoradiotherapy in glioblastoma J. Clin. Oncol. 26 2008 3015 3024
46. L. Vormittag Co-expression of Bmi-1 and podoplanin predicts overall survival in patients with squamous cell carcinoma of the head and neck treated with radio(chemo)therapy Int. J. Radiat. Oncol. Biol. Phys. 73 2009 913 918
47. K. Vrzalikova Prognostic value of Bmi-1 oncoprotein expression in NSCLC patients: a tissue microarray study J. Cancer Res. Clin. Oncol. 134 2008 1037 1042
48. H. Yasuda Elevated CD133, but not VEGF or EGFR, as a predictive marker of distant recurrence after preoperative chemoradiotherapy in rectal cancer Oncol. Rep. 22 2009 709 717
49. K.L. Schaefer Microarray analysis of Ewing's sarcoma family of tumours reveals characteristic gene expression signatures associated with metastasis and resistance to chemotherapy Eur. J. Cancer 44 2008 699 709
50. R. Yoshikawa Hedgehog signal activation in oesophageal cancer patients undergoing neoadjuvant chemoradiotherapy Br. J. Cancer 98 2008 1670 1674 (Pubitemid 351684687)
51. A.V. Salnikov CD133 is indicative for a resistance phenotype but does not represent a prognostic marker for survival of non-small cell lung cancer patients Int. J. Cancer 126 2010 950 958
52. R. Danesi Pharmacogenetics of anticancer drug sensitivity in non-small cell lung cancer Pharmacol. Rev. 55 2003 57 103 (Pubitemid 36268399)
53. X. Fan NOTCH pathway blockade depletes CD133-positive glioblastoma cells and inhibits growth of tumor neurospheres and xenografts Stem Cells 28 2010 5 16
54. T. Palomero, and A. Ferrando Therapeutic targeting of NOTCH1 signaling in T-cell acute lymphoblastic leukemia Clin Lymphoma Myeloma 9 Suppl 3 2009 S205 210
55. B. Westhoff Alterations of the Notch pathway in lung cancer Proc. Natl. Acad. Sci. U.S.A. 106 2009 22293 22298
56. J.T. Park Notch3 gene amplification in ovarian cancer Cancer Res. 66 2006 6312 6318
57. S.H. Lee Mutational analysis of NOTCH1, 2, 3 and 4 genes in common solid cancers and acute leukemias APMIS 115 2007 1357 1363
58. Y.P. Fu NOTCH2 in breast cancer: association of SNP rs11249433 with gene expression in ER-positive breast tumors without TP53 mutations Mol Cancer 9 2010 113
59. M.A. Villaronga HEY1 Leu94Met gene polymorphism dramatically modifies its biological functions Oncogene 29 2010 411 420
60. L.S. Hart, and W.S. El-Deiry Invincible, but not invisible: imaging approaches toward in vivo detection of cancer stem cells J. Clin. Oncol. 26 2008 2901 2910
61. C. Heyn In vivo MRI of cancer cell fate at the single-cell level in a mouse model of breast cancer metastasis to the brain Magn. Reson. Med. 56 2006 1001 1010 (Pubitemid 44691342)
62. S. Riethdorf Review: Biological relevance of disseminated tumor cells in cancer patients Int. J. Cancer 123 2008 1991 2006
63. M. Balic Most early disseminated cancer cells detected in bone marrow of breast cancer patients have a putative breast cancer stem cell phenotype Clin. Cancer Res. 12 2006 5615 5621 (Pubitemid 44629587)
64. P.A. Theodoropoulos Circulating tumor cells with a putative stem cell phenotype in peripheral blood of patients with breast cancer Cancer Lett. 288 2009 99 106
65. J.E. Lang Significance of micrometastasis in bone marrow and blood of operable breast cancer patients: research tool or clinical application? Expert Rev. Anticancer Ther. 7 2007 1463 1472 (Pubitemid 351826911)
66. M.J. Slade, and R.C. Coombes The clinical significance of disseminated tumor cells in breast cancer Nat. Clin. Pract. Oncol. 4 2007 30 41 (Pubitemid 46017692)
67. P. Therasse New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada J. Natl. Cancer Inst. 92 2000 205 216
68. J.M. Llovet Sorafenib in advanced hepatocellular carcinoma N. Engl. J. Med. 359 2008 378 390
69. E.M. Hurt CD44+ CD24(-) prostate cells are early cancer progenitor/stem cells that provide a model for patients with poor prognosis Br. J. Cancer 98 2008 756 765 (Pubitemid 351272625)
70. B. Seruga Cytokines and their relationship to the symptoms and outcome of cancer Nat. Rev. Cancer 8 2008 887 899
71. R. Salgado Circulating interleukin-6 predicts survival in patients with metastatic breast cancer Int. J. Cancer 103 2003 642 646 (Pubitemid 36091468)
72. P. Sansone IL-6 triggers malignant features in mammospheres from human ductal breast carcinoma and normal mammary gland J. Clin. Invest. 117 2007 3988 4002 (Pubitemid 350224108)
73. N. Funel Laser microdissection and primary cell cultures improve pharmacogenetic analysis in pancreatic adenocarcinoma Lab. Invest. 88 2008 773 784 (Pubitemid 351896636)
74. H.S. Robins Comprehensive assessment of T-cell receptor beta-chain diversity in alphabeta T cells Blood 114 2009 4099 4107
75. M.J. Grimshaw Mammosphere culture of metastatic breast cancer cells enriches for tumorigenic breast cancer cells Breast Cancer Res. 10 2008 R52
76. X. Huang Isolation, enrichment, and maintenance of medulloblastoma stem cells J. Vis. Exp. 2010 10.3791/2086
77. M.A. Duhagon Genomic profiling of tumor initiating prostatospheres BMC Genomics 11 2010 324
78. I.P. Garraway Human prostate sphere-forming cells represent a subset of basal epithelial cells capable of glandular regeneration in vivo Prostate 70 2010 491 501
79. A. Dubrovska The role of PTEN/Akt/PI3K signaling in the maintenance and viability of prostate cancer stem-like cell populations Proc. Natl. Acad. Sci. U.S.A. 106 2009 268 273